News | PET Imaging | September 01, 2016

ASNC, SNMMI Support Myocardial Perfusion PET in Coronary Artery Disease Diagnosis, Management

Joint position statement provides guidance on when imaging technique should be considered for optimal patient care

ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) e-published a new position statement supporting myocardial perfusion positron emission tomography (PET) in the diagnosis and management of coronary artery disease. The statement explains why it is the most useful imaging modality and provides guidance as to when it should be considered for optimal patient care.

The Position Paper states that, in view of its high diagnostic accuracy, strong prognostic power, low radiation dose and consistent high-quality images, myocardial perfusion PET should be considered the preferred, first-line test for all patients who meet the appropriate criteria for a stress imaging test, are unable to complete a diagnostic-level of exercise and require pharmacologic stress. Myocardial perfusion PET is also the recommended test when previous stress imaging is equivocal, of poor quality or inconclusive; in high-risk patients in whom diagnostic errors carry even greater clinical implications; in patients with certain body characteristics that commonly affect image quality; and in younger patients to minimize accumulated life-time radiation exposure.

Bracco Diagnostics manufactures the only U.S. Food and Drug Administration (FDA)-approved generator-based PET perfusion agent for the evaluation of patients with suspected or existing coronary artery disease.

Read the full statement here

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste